Arbutus and Barinthus announce new data from IM-PROVE II trial
Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...
Akero to showcase new analyses of Phase 2b HARMONY study at AASLD
Akero Therapeutics (AKRO) announced results of analyses supporting the clinical activity of efruxifermin in metabolic dysfunction-associated ...
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
TMCnet2d
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...
Science Daily2d
We may be overestimating the association between gut bacteria and disease, machine learning study finds
Many bacterial-linked illnesses, such as inflammatory bowel disease or colorectal cancer, are associated with an overgrowth of gut bacteria thought to be bad actors. But when researchers used a ...
eLife2d
Dynamics of compartment-specific proteomic landscapes of hepatotoxic and cholestatic models of liver fibrosis
Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...
First for Women on MSN3d
Here's Why You Don't Want to Skip That Cup of Coffee
T here's no part of the morning routine as sacred to so many of us as that first sip of freshly brewed coffee. In fact, most ...
TMCnet3d
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...
New guidelines for treatment of Type 2 diabetes from International Diabetes Federation soon
IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.
Medindia4d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Canada NewsWire MISSISSAUGA, ON, Nov. 12, 2024 MISSISSAUGA, ON, Nov. 12, 2024 /CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment o ...